{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEET\tDecember 31,\tDecember 31,\t(In millions except share and per share amounts)\t2022\t2021\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t8,524\t$\t4,477\tAccounts receivable, less allowances of $\t189\tand $\t150\t8,115\t7,977\tInventories\t5,634\t5,051\tContract assets, net\t1,312\t968\tOther current assets\t1,644\t1,640\tTotal current assets\t25,229\t20,113\tProperty, plant and equipment, net\t9,280\t8,333\tAcquisition-related intangible assets, net\t17,442\t20,113\tOther assets\t4,007\t4,640\tGoodwill\t41,196\t41,924\tTotal assets\t$\t97,154\t$\t95,123\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t5,579\t$\t2,537\tAccounts payable\t3,381\t2,867\tAccrued payroll and employee benefits\t2,095\t2,427\tContract liabilities\t2,601\t2,655\tOther accrued expenses\t3,354\t2,950\tTotal current liabilities\t17,010\t13,436\tDeferred income taxes\t2,849\t3,837\tOther long-term liabilities\t4,238\t4,540\tLong-term obligations\t28,909\t32,333\tCommitments and contingencies (Note 12)\tRedeemable noncontrolling interest\t116\t122\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t440,668,112\tand\t439,154,741\tshares issued\t441\t439\tCapital in excess of par value\t16,743\t16,174\tRetained earnings\t41,910\t35,431\tTreasury stock at cost,\t50,157,275\tand\t44,720,112\tshares\t(\t12,017\t)\t(\t8,922\t)\tAccumulated other comprehensive items\t(\t3,099\t)\t(\t2,329\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t43,978\t40,793\tNoncontrolling interests\t54\t62\tTotal equity\t44,032\t40,855\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t97,154\t$\t95,123\tThe accompanying notes are an integral part of these consolidated financial statements.\tF-5\tTHERMO FISHER SCIENTIFIC INC.\tCONSOLIDATED STATEMENT OF INCOME\tYear Ended\tDecember 31,\tDecember 31,\tDecember 31,\t(In millions except per share amounts)\t2022\t2021\t2020\tRevenues\tProduct revenues\t$\t28,548\t$\t30,361\t$\t25,306\tService revenues\t16,367\t8,850\t6,912\tTotal revenues\t44,915\t39,211\t32,218\tCosts and operating expenses:\tCost of product revenues\t14,247\t13,594\t11,407\tCost of service revenues\t11,697\t5,979\t4,807\tSelling, general and administrative expenses\t8,993\t8,007\t6,930\tResearch and development expenses\t1,471\t1,406\t1,181\tRestructuring and other costs\t114\t197\t99\tTotal costs and operating expenses\t36,522\t29,183\t24,424\tOperating income\t8,393\t10,028\t7,794\tInterest income\t272\t43\t65\tInterest expense\t(\t726\t)\t(\t536\t)\t(\t553\t)\tOther income/(expense)\t(\t104\t)\t(\t694\t)\t(\t76\t)\tIncome before income taxes\t7,835\t8,841\t7,230\tProvision for income taxes\t(\t703\t)\t(\t1,109\t)\t(\t850\t)\tEquity in earnings/(losses) of unconsolidated entities\t(\t172\t)\t(\t4\t)\t(\t3\t)\tNet income\t6,960\t7,728\t6,377\tLess: net income attributable to noncontrolling interests and redeemable noncontrolling interest\t10\t3\t2\tNet income attributable to Thermo Fisher Scientific Inc.\t$\t6,9"
        ],
        "timestamp": "2025-01-21_09-41-31"
    }
}